(CDAX, Real Estate, DEF GR)



Buy
EUR 26.90

Price EUR 24.40
Upside 10.2 %

NAV (WRe) 23e:	28.45	ESG Score (MSCI
FFO-Yield 23e:	25.34	Balance Sheet Sco
		Market Liquidity So
Market Snapshot:	EUR m	Shareholders:
Market cap:	107.85	Freefloat
No. of shares (m):	4.42	MSC Invest GmbH
Freefloat MC:	70.10	Geminus GmbH
Ø Trad. Vol. (30d):	23.63 th	Supervisory board

Value Indicators:

Warburg ESG Risk Score:	2.3
ESG Score (MSCI based):	3.0
Balance Sheet Score:	3.8
Market Liquidity Score:	0.0
Shareholders:	
Freefloat	65.0 %
MSC Invest GmbH	29.0 %

4.0 %

2.0 %

Description:	
Commercial real estate company focused on retail parks in Northern and Eastern Germany	

	Key Figures (WRe):	2021e
)	LTV:	58.1 %
)	Equity Ratio:	17.8 %
)		
,		

### FY acquisition target already exceeded

■ DEFAMA has recently announced two acquisitions with an investment volume of EUR 5.9m, thus already significantly exceeding its targeted annual acquisition volume of EUR 15-20m (ytd 24.2m) in 2021. The company bought a retail park near Kassel with a lettable space of 8.3k sqm for EUR 4.5m. This is an attractive rent multiple of ~10 (rent of EUR 450k) and leads to a price per sqm of EUR 543. Core tenants are a DIY store (Hercules) of the Edeka Group and a furniture store. The property has a good location and there is no space in the area for a new construction that could replace this property. We believe there may be some rental potential for the property in the medium term. The second property acquired is a property in Barsinghausen with a lettable space of 900 sqm and the tenants Rossmann and a driving school. The property is located in the immediate vicinity of the pedestrian zone. DEFAMA paid a purchase price of EUR 1.4m (900 sqm), which corresponds to a multiple of 11 on the net annual rent.

EUR

- Furthermore, DEFAMA has made progress in reducing vacancies in several properties already owned, e.g. in Sonnefeld, Albstadt and Staßfurt, and should also be successful with an expected contract with a new well-known retailer of pet supplies in Gardelegen (acquired in 2021 in a foreclosure sale), which reduces the vacancy in this property to approx. 33%. In addition, DEFAMA was able to achieve lease extensions at several properties without additional investments.
- Against this background, DEFAMA has already exceeded its annualised FFO target for the end of 2021 of EUR 8m with EUR 8.2m. As the latest three deals already fully support 2022, our current FFO estimate for 2022 of EUR 8.36m looks conservative and offers some upside given that 2021 has almost three months left and the deal pipeline remains attractive.
- We stick to Buy with a price target of EUR 26.90.




Rel. Performance vs CDAX:	
1 month:	4.1 %
6 months:	29.1 %
Year to date:	15.7 %
Trailing 12 months:	6.7 %

FY End: 31.12.	CAGR							
in EUR m	(20-23e)	2017	2018	2019	2020	2021e	2022e	2023e
Rental income		5.10	7.61	9.53	12.19	14.93	16.89	18.95
Change yoy		67.9 %	49.2 %	25.1 %	27.9 %	22.5 %	13.2 %	12.2 %
EBIT		2.67	3.59	4.50	5.62	9.28	7.68	8.62
FFO I		2.58	3.65	4.62	5.87	7.25	8.36	9.46
FFO I-margin		50.6 %	47.9 %	48.4 %	48.2 %	48.6 %	49.5 %	49.9 %
EBT		1.77	2.25	2.78	3.49	6.67	4.76	5.43
Net income		1.36	1.68	2.06	2.51	5.13	3.53	4.05
EPS		0.38	0.46	0.51	0.57	1.16	0.80	0.92
FFOPS I		0.73	1.01	1.14	1.33	1.64	1.89	2.14
DPS		0.34	0.40	0.45	0.48	0.55	0.60	0.65
Dividend Yield		3.8 %	3.4 %	2.9 %	2.7 %	2.3 %	2.5 %	2.7 %
Book Value / Share		3.18	4.10	5.50	5.61	6.22	6.42	6.69
P/E		23.2 x	25.0 x	30.1 x	30.9 x	21.0 x	30.6 x	26.7 x
Price / Book		2.8 x	2.6 x	2.5 x	3.1 x	3.9 x	3.8 x	3.6 x
P / NAVPS		1.1 x	1.2 x	1.3 x	1.2 x	1.4 x	1.3 x	1.2 x
FFO I-Yield		8.2 %	8.7 %	7.5 %	7.6 %	6.7 %	7.7 %	8.8 %
ROE		12.4 %	12.3 %	10.2 %	10.2 %	19.6 %	12.6 %	14.0 %
LTV		61.1 %	62.0 %	58.2 %	60.2 %	58.1 %	59.1 %	59.5 %
Guidance:	2021e: FFO	of EUR ~7.1m	ı, Net profit (I	HGB) of EUR	: >5.0m			

Company events:



# **EPRA-NAV** per share development in EUR



Source: Warburg Research

# FFO per share development in EUR 2.000 1.750 1.500 1.250 1.000 0.750 0.500 0.250 0.000

Source: Warburg Research

## **Company Background**


- Founded in 2014 and headquartered in Berlin, DEFAMA focuses on the acquisition, ownership and management of retail parks in German small and medium-sized cities, predominantly in Northern and Eastern Germany.
- The investment strategy is to "buy and hold" assets with high occupancy and minor capex needs for a purchase price of ~10x annual rent.
- Investment volumes are EUR 1 5 million per asset. Anchor tenants are nationwide retailers.

## **Competitive Quality**

- Real estate competence: founder, major shareholder and CEO Matthias Schrade, previously oversaw as a board member responsible for acquisitions for a non-listed real estate company based in Munich.
- Unique focus: the company competes for assets that are too large for individual investors and too small for institutional investors and can "buy low".
- Strong access to local public banks networks, for whom real estate financings for DEFAMA projects are large and important deals. They in turn know smaller tenants well.
- Focus on leading centers in smaller cities ("big fish in a small pond").


# Geographical breakdown of rental income

% of total rental income



## Rental income by sector

% of rental income




Source: Warburg Research



Valuation							
	2017	2018	2019	2020	2021e	2022e	2023e
P/E	23.2 x	25.0 x	30.1 x	30.9 x	21.0 x	30.6 x	26.7 x
P / NAVPS	1.1 x	1.2 x	1.3 x	1.2 x	1.4 x	1.3 x	1.2 x
Price / Book	2.8 x	2.6 x	2.5 x	3.1 x	3.9 x	3.8 x	3.6 x
P / FFOPS I	12.2 x	11.5 x	13.4 x	13.2 x	14.9 x	12.9 x	11.4 x
FFO I-Yield	8.2 %	8.7 %	7.5 %	7.6 %	6.7 %	7.7 %	8.8 %
ROE	12.4 %	12.3 %	10.2 %	10.2 %	19.6 %	12.6 %	14.0 %
Equity Ratio	21 %	19 %	24 %	18 %	18 %	17 %	16 %

Company Specific Items							
	2017	2018	2019	2020	2021e	2022e	2023e
NAV/Share	8.42	11.02	13.46	16.86	18.85	20.21	21.78
Vacancy Rate	2.7 %	4.3 %	4.0 %	3.7 %	3.7 %	4.0 %	4.0 %






Consolidated profit and loss							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023
Total revenues	5.83	9.09	11.21	14.58	17.77	20.11	22.5
Rental income	5.10	7.61	9.53	12.19	14.93	16.89	18.9
Change yoy	67.9 %	49.2 %	25.1 %	27.9 %	22.5 %	13.2 %	12.2 %
Property operating costs	1.24	2.21	2.63	3.40	4.21	4.67	5.23
Property management costs	0.00	0.00	0.00	0.00	0.00	0.00	0.0
Rental profit	4.58	6.87	8.57	11.18	13.56	15.45	17.3
Income from property sales	0.00	0.00	0.00	0.00	2.60	0.00	0.0
Other revenues	0.12	0.08	0.07	0.12	0.25	0.24	0.2
Gross profit	4.70	6.95	8.64	11.30	16.41	15.69	17.59
Administration expenses	0.35	0.70	0.70	0.81	1.00	1.13	1.26
Personnel expenses	0.47	0.72	1.04	1.50	1.83	2.05	2.30
Other operating income/expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unfrequent items	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a
EBITDA	3.89	5.53	7.04	8.99	13.58	12.51	14.03
Valuation result	0.00	0.00	0.00	0.00	2.60	0.00	0.00
Depreciation of fixed assets	1.22	1.95	2.55	3.36	4.30	4.83	5.41
EBITA	2.67	3.59	4.50	5.62	9.28	7.68	8.62
Amortisation of intangible assets/Goodwill	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT	2.67	3.59	4.50	5.62	9.28	7.68	8.62
Interest income	0.00	0.00	0.01	0.01	0.00	0.00	0.00
Interest expenses	0.90	1.34	1.73	2.14	2.62	2.93	3.19
Other financial income (loss)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial result	-0.90	-1.34	-1.72	-2.13	-2.62	-2.93	-3.19
EBT	1.77	2.25	2.78	3.49	6.67	4.76	5.43
Margin	30.4 %	24.8 %	24.8 %	24.0 %	37.5 %	23.6 %	24.1 %
Total taxes	-0.41	-0.55	-0.71	-0.71	-0.71	-1.22	-1.38
thereof cash taxes	-0.28	-0.36	-0.42	-0.42	-0.42	-0.72	-0.83
Net income from continuing operations	1.36	1.70	2.07	2.51	5.14	3.53	4.0
Income from discontinued operations (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net income before minorities	1.36	1.70	2.07	2.51	5.14	3.53	4.0
Minority interest	0.00	0.02	0.01	0.00	0.00	0.00	0.00
Net income	1.36	1.68	2.06	2.51	5.13	3.53	4.0
Number of shares, average	3.55	3.62	4.05	4.42	4.42	4.42	4.42
FFO (II)	2.58	3.65	4.62	5.87	7.25	8.36	9.46
FFO I-margin	50.6 %	47.9 %	48.4 %	48.2 %	48.6 %	49.5 %	49.9 %
FFOPS I	0.73	1.01	1.14	1.33	1.64	1.89	2.14
EPS	0.38	0.46	0.51	0.57	1.16	0.80	0.92
EPS adj.	0.38	0.43	0.47	0.57	1.16	0.80	0.92
Adjustments made for:							

Guidance: 2021e: FFO of EUR ~7.1m, Net profit (HGB) of EUR >5.0m

Financial Ratios							
	2017	2018	2019	2020	2021e	2022e	2023e
Property operating costs / Rental Income	24.4 %	29.1 %	27.6 %	27.9 %	28.2 %	27.6 %	27.6 %
Operating Leverage (Real Estate)	2.4 x	2.9 x	5.0 x	4.6 x	5.5 x	8.8 x	9.3 x
Rental profit / interest expenses	5.1 x	5.1 x	5.0 x	5.2 x	5.2 x	5.3 x	5.4 x





Net Financial Debt


LTV

**Equity Ratio** 

Net Fin. Debt / EBITDA



Consolidated balance sheet							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023
Assets							
Goodwill and other intangible assets	0.01	0.01	0.03	0.02	0.02	0.02	0.02
thereof other intangible assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00
thereof Goodwill	0.01	0.01	0.03	0.02	0.02	0.02	0.02
Property, plant and equipment	0.03	0.08	0.11	1.39	1.41	1.42	1.43
Investment properties	51.96	81.10	93.14	127.79	141.76	156.61	170.85
Financial assets	0.24	0.26	1.70	0.12	0.45	0.45	0.45
Other long-term assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed assets	52.24	81.44	94.98	129.33	143.64	158.50	172.75
Inventories	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts receivable	0.22	0.51	0.00	0.80	0.91	0.93	0.95
Liquid assets	2.49	2.80	6.98	4.28	11.46	8.07	8.03
Other short-term assets	0.83	0.59	-2.56	-0.66	-7.95	-4.58	-4.56
Current assets	3.17	4.34	9.29	7.38	13.39	10.01	10.01
Total Assets	55.41	85.79	104.28	136.71	157.02	168.51	182.76
Liabilities and shareholders' equity							
Subscribed capital	3.55	3.90	4.42	4.42	4.42	4.42	4.42
Capital reserve	6.15	10.03	17.31	17.31	17.31	17.31	17.31
Retained earnings	1.59	2.06	2.56	3.07	5.78	6.65	7.83
Other equity components	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Shareholders' equity	11.29	15.99	24.29	24.81	27.51	28.39	29.56
Minority interest	0.10	0.38	0.39	0.40	0.40	0.40	0.40
Provisions	0.36	1.01	0.43	0.51	0.51	0.51	0.51
thereof provisions for pensions and similar obligations	0.18	0.21	0.21	0.25	0.25	0.25	0.25
Financial liabilities (total)	43.07	67.79	76.52	110.25	127.74	138.35	151.43
Short-term financial liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts payable	0.19	0.30	0.51	0.29	0.42	0.42	0.42
Other liabilities	0.51	0.70	2.54	0.86	0.84	0.84	0.84
Liabilities	44.13	69.79	79.99	111.91	129.51	140.12	153.20
Total liabilities and shareholders' equity	55.41	85.79	104.28	136.71	157.02	168.51	182.76
Financial Ratios							
i ilialiciai Natios	2047	2040	2040	2020	0004-	2022-	2022-
	2017	2018	2019	2020	2021e	2022e	2023e
Return on Capital							
ROA	3.1 %	2.4 %	2.2 %	2.1 %	3.5 %	2.2 %	2.3 %
ROE	12.4 %	12.3 %	10.2 %	10.2 %	19.6 %	12.6 %	14.0 %
FFO I / Equity	0.2 x	0.3 x	0.2 x	0.2 x	0.3 x	0.3 x	0.3 x
Solvency							
Net Debt	40.76	65.20	69.75	106.23	116.53	130.54	143.66
Not Financial Daht	40.50	04.00	00.54	405.00	440.00	400.00	440 44



40.58

10.4 x

61.1 %

20.5 %

64.99

11.7 x

62.0 %

19.1 %

69.54

9.9 x

58.2 %

23.7 %

105.98

11.8 x

60.2 %

18.4 %

116.28

58.1 %

17.8 %

8.6 x

130.28

10.4 x

59.1 %

17.1 %

143.41

10.2 x

59.5 %


16.4 %



Consolidated cash flow statement							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net cash provided by operating activities [1] Net cash provided by investing activities [2] Net cash provided by financing activities [3]	2.76	3.42	3.80	4.96	9.68	8.43	9.53
	-21.95	-31.12	-16.09	-37.91	-17.84	-20.00	-20.00
	20.23	28.01	16.47	30.25	15.34	8.18	10.43
Change in liquid funds [1]+[2]+[3] Effects of exchange-rate changes on cash Cash and cash equivalent at end of period	1.03	0.31	4.18	-2.70	7.18	-3.39	-0.04
	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	<b>2.49</b>	<b>2.80</b>	<b>6.98</b>	<b>4.28</b>	<b>11.46</b>	<b>8.07</b>	<b>8.03</b>

Financial Ratios							
	2017	2018	2019	2020	2021e	2022e	2023e
Cash Flow							
FFO (II)	2.58	3.65	4.62	5.87	7.25	8.36	9.46
FFOPS I	0.73	1.01	1.14	1.33	1.64	1.89	2.14
FFOPS I diluted	0.73	0.94	1.04	1.33	1.64	1.89	2.14
FFO I-Yield	8.2 %	8.7 %	7.5 %	7.6 %	6.7 %	7.7 %	8.8 %
FFO I-margin	50.6 %	47.9 %	48.4 %	48.2 %	48.6 %	49.5 %	49.9 %
Interest Paid / Avg. Debt	2.8 %	2.4 %	2.4 %	2.3 %	2.2 %	2.2 %	2.2 %
Management of Funds							
Capex/Investment Properties	-42.3 %	-38.4 %	-17.3 %	-29.7 %	-12.6 %	-12.8 %	-11.7 %
Avg. Working Capital / Sales	0.7 %	1.4 %	-1.3 %	0.0 %	2.8 %	2.5 %	2.3 %
Dividend Payout Ratio	88.6 %	85.1 %	88.2 %	84.5 %	47.3 %	75.1 %	70.9 %

## FFO



Source: Warburg Research



#### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).



#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
DEFAMA Deutsche Fachmarkt AG	5	http://www.mmwarburg.com/disclaimer/disclaimer en/DE000A13SUL5.htm

9



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY I	RATING

Rating	Number of stocks	% of Universe
Buy	145	67
Hold	60	28
Sell	7	3
Rating suspended	3	1
Total	215	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	46	78
Hold	11	19
Sell	0	0
Rating suspended	2	3
Total	59	100

#### PRICE AND RATING HISTORY DEFAMA DEUTSCHE FACHMARKT AG AS OF 08.10.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



Matthias Rode Head of Equilies mode @makes with a 49 40 309837-280 RESEARCH Michael Holder Head of Research						
	EQUITIES					
Michael Holdor   Holdor   Holdor   Hold of Signatury research on Medicing/Swarbury research on Honor Rischmeler   Hold of Signatury research on Honor Rischmeler   Hold of Signatury research on Honor Rischmeler   Holdor Holdor Rischmeler   Holdo	Matthias Rode Head of Equities					
Head of Rosearch Inholoid@wathung-research.com Heanner Rüschmieler Heanner Heanner Heanner Rüschmieler Heanner	RESEARCH					
Head of Research						
Description						
Jan Bauer	Stefan Augustin					
Banetis   Jauser  Symathury research.com   Johns Blum   449 40 308537-2170   Telco, Modia, Construction   jiblum Symathury research.com   Johns Blum   449 40 308537-2170   Telco, Modia, Construction   jiblum Symathury research.com   Technology   machaumann Symathury-research.com   Technology   machaumann Symathury-research.com   Technology   machaumann Symathury-research.com   Technology   Telco, Modia, Construction   149 40 309537-125   Industrials & Transportation   cochrisign/Symathury-research.com   Technology   Telco, Modia, Construction   149 40 309537-125   Telco, Modia, Mod			• •			
Technology						
Inclustrials & Transportation   cochne@warburg-research.com   Dr. Christan Ehmann   44.9 4.9 308537-167   BioTech, Life Science   cehnann@warburg-research.com   Marchanna   44.9 4.0 308537-162   Real Estate   sapping@warburg-research.com   August   August						
Dr. Christaina Ehmann BioTech. Life Science cohmann@warburg-research.com Felix Ellmann 4.94 0.309537-1205 Schware. IT feliman@warburg-research.com Jörg Philipp Frey Relia Consumer Coods Infrowerburg-research.com Martus Fuhrberg H-94 0.309537-258 Infrancial Schware. IT H-94 0.309537-258 Infrancial Schware. IT H-94 0.309537-259 Infrancial Schware. IT H-94 0.309537-250 Infrancial Schware. IT H-94 0.309537-250 Infrancial Schware. IT H-94 0.309537-255 Infrancial Schware. IT Infrancial Sc						
BioTech, Life Science cohmani@warburg-research.com Felix Ellmann 14-9.4 0.309537-120 Caps United Finding Philipp Frey Felix Ellmann 14-9.4 0.309537-268 Relaid. Consumer Goods Infre@warburg-research.com 14-9.4 0.309537-285 Finding Services Infraed Bear 14-9.4 0.309537-285 Finding Services Infraed Bear 14-9.4 0.309537-230 Marc-René Tonn 14-9.4 0.309537-230 Mustafa Hidir 14-	·		, •			
Software, IT fellmann@warburg-research.com Jorg Philipp Frey Has 94 03 09557-258 Retail. Consumer Goods [flwy@warburg-research.com Harbriborg] Has 94 03 09557-255 Financial Services mfurbrborg Has 94 03 09557-255 Historical Services mfurbrborg Has 94 03 09557-255 Historical Services mfurbrborg Has 94 03 09557-255 Historical Services Micro Harbridge Warburg-research.com Hash 167 Warburg-researc	BioTech, Life Science	cehmann@warburg-research.com	Real Estate	sstippig@warburg-research.com		
Jürg Philipp Frey Retail Consumer Goods    fijev@warburg-research.com   4.94 do 309537-258   Automobiles, Car Suppliers   4.94 do 309537-285   Technology   National Services   Marcy Repearation   4.94 do 309537-280   Technology   National Services   Marcy Repearation   4.94 do 309537-290   Marcy Repearation   4.9						
Financial Services	Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258	Marc-René Tonn	+49 40 309537-259		
Mustafa Hidir         4.49 40 309537-230 whidir@warburg-research.com         Andreas Wolf schware, IT         4.49 40 309537-430 schware, IT         4.49 40 309537-430 awoll@warburg-research.com           Ulrich Huwald Health Care, Pharma         4.49 40 309537-255 uhuwaki@warburg-research.com         Schware, IT         Aworlingwarburg-research.com           INSTITUTIONAL EQUITY SALES         Warman         4.49 40 3282-2660 uhuwakigwarburg-research.com         Maximilian Martin         4.49 69 5050-7413 Austria, Poland         4.49 69 5050-7413 Austria, Poland         Austria, Poland         mmartingmmwarburg-ugon         4.49 40 3282-2665 beckmany         Christopher Seedorf         4.49 40 4282-2665 beckmany         Switzerland         4.49 40 3282-2665 beckmany         Maximilian Martin         4.49 69 5050-7413 Austria         Austria, Poland         Mmartingmmwarburg-ugon         Christopher Seedorf         4.49 40 3282-2665 beckmented figuity Sales, Germany         4.49 40 3282-2666 beckmented figuity Sales, Germany         4.49 40 3282-2669 beckmented figuity Sales, Germany	Marius Fuhrberg	+49 40 309537-185				
Automobiles, Car Suppliers mhidi@warburg-research.com Urrich Huwald 449 40 309537-255 thuwald@warburg-tesearch.com Warshin Care, Pharma have defeated by the alth Care, Pharma			•,			
Ulrich Huwald Health Care, Pharma buwald@warburg-research.com bleath Care, Pharma buwald@warburg-research.com bleath Care, Pharma buwald@warburg-research.com buwald@warburg-research.com burbuwald@warburg-research.com burbuwald@warburg-research.com burbuwald@warburg-research.com burburg-research.com bur						
Marc Niemann	Ulrich Huwald					
Marc Niemann         +49 40 3282-2660 flead of Equity Sales, Germany         Maximillian martin         449 69 5050-7413 mmartin@mmwarburg.com           Klaus Schilling         4+9 49 59 5050-7400 clear of Equity Sales, Germany         kschilling@mmwarburg.com         5 witzerland         5 witzerland         5 witzerland         49 69 5050-7413 mmarting.com         5 witzerland         6 witzerland         7 witzer	Health Care, Pharma	uhuwald@warburg-research.com				
Head of Equity Sales, Germany Klaus Schilling Hady Sales, Germany Klaus Schilling Hady Sales, Germany Kabilling@mmwarburg.com Kabilling@mmwarburg.com Kabilling@mmwarburg.com Kabilling@mmwarburg.com Kabilling@mmwarburg.com Lea Bogdanova Lea Hagy Sol50-7411 United Kingdom, Ireland Lone Hagy Sol50-7415 Scandinavia, Austria Lone Hagy Sol50-7415 Lone Hagy Sol50-7415 Scandinavia, Austria Lone Hagy Sol50-7415 Scandinavia, Austria Lone Hagy Sol50-7415 Lone Hagy Sol50-7415 Scandinavia, Austria Lone Hagy Sol50-7415 Scandinavia, Austria Lone Hagy Sol50-7415 Lone Hagy Sol50-7415 Lone Hagy Sol50-7415 Lone Hagy Sol50-7417 Lone Hagy Sol50-7415 Lone Hagy Sol50-7417 Lone Hagy Sol50-7415 Lone Hagy Sol50-7417 Lone Hagy Sol50-	INSTITUTIONAL EQU	ITY SALES				
Klaus Schilling						
Head of Equity Sales, Germany						
Tim Beckmann United Kingdom United Kingdom United Kingdom United Kingdom United Kingdom, Ireland United Kingdom  Alexander Eschweiler H49 40 3282-2669 Sophie Hauer Roadshow/Marketing Roadshow/Marketing Shauer@mmwarburg.com Alexander Firsch United Kingdom  Alexander Eschweiler H49 40 3282-2696 United Kingdom H49 40 3282-2696 Haad Sela Trading H49 40 3282-2698 Haad Sela Trading H49 40 3282-2662 Haad S						
Lea Bogdanova				9		
United Kingdom, Ireland Jens Buchmüller  +49 69 5050-7415 Scandinavia, Austria jbuchmueller@mmwarburg.com Alexander Eschweiler Alexander Haugen Alexander Alexan	•					
Jens Buchmüller Scandinavia, Austria jbuchmueller@mmwarburg.com Alexander Eschweiler Germany, Luxembourg aeschweiler@mmwarburg.com Matthias Fritsch United Kingdom Marthias Fritsch United Kingdom Matthias Fritsch  H49 40 3282-2696  Juliane Niemann Roadshow/Marketing Macel Magiera  H49 40 3282-2662  Sales Trading Malgera  H49 40 3282-2662  Bastian Quast  H49 40 3282-2702  Bastian Quast  H49 40 3282-2702  Bastian Quast  H49 40 3282-2702  Bastian Quast  H49 40 3282-2703  Jörg Treptow  H49 40 3282-2658  Macco Research  Macco Research  Macco Research  Carsten Klude  H49 40 3282-2702  Macro Research  Carsten Klude  H49 40 3282-2702  Macro Research  Carsten Klude  H49 40 3282-2702  Macro Research  Research  Roadshow/Marketing  Marcel Magiera  H49 40 3282-2662  Bastian Quast  H49 40 3282-2662  Bastian Quast  H49 40 3282-2662  Bastian Quast  H49 40 3282-2700  Jörg Treptow  H49 40 3282-2658  Juliane Niemann  H49 40 3282-2668  Bastian Quast  H49 40 3282-2700  Jörg Treptow  H49 40 3282-2658  Juliane Niemann  H49 40 3282-2668  Bastian Quast  H49 40 3282-2662  Bastian Quast  H49 40 3282-2700  Jörg Treptow  H49 40 3282-2658  Juliane Niemann  H49 40 3282-2662  Bastian Quast  H49 40 3282-2658  Juliane Niemann  H49 40 3282-2662  Bastian Quast  H49 40 3282-2662  Bastian Qua						
Alexander Eschweiler         449 40 3282-2669         Sophie Hauer         449 69 5050-7417           Germany, Luxembourg         aeschweiler@mmwarburg.com         Roadshow/Marketing         shauer@mmwarburg.com           Matthias Fritsch         +49 40 3282-2696         Juliane Niemann         +49 40 3282-2690           United Kingdom         mfritsch@mmwarburg.com         Roadshow/Marketing         jniemann@mmwarburg.com           SALES TRADING           Oliver Merckel         +49 40 3282-2634         Marcel Magiera         +49 40 3282-2662           Head of Sales Trading         omerckel@mmwarburg.com         Sales Trading         mmagiera@mmwarburg.com           Elyaz Dust         +49 40 3282-2702         Bastian Quast         +49 40 3282-2701           Sales Trading         edust@mmwarburg.com         Sales Trading         bquast@mmwarburg.com           Michael Ilgenstein         +49 40 3282-2702         Jörg Treptow         +49 40 3282-2652           Sales Trading         milgenstein@mmwarburg.com         Sales Trading         jtreptow@mmwarburg.com           MACRO RESEARCH         Carsten Klude         +49 40 3282-2572         Dr. Christian Jasperneite         +49 40 3282-2439           Macro Research         research.mmwarburg.com/en/index.html         Refinitiv         www.refinitiv.com           B	<del>-</del>					
Germany, Luxembourg aeschweiler@mmwarburg.com Matthias Fritsch United Kingdom mfritsch@mmwarburg.com Match in Spritsch United Kingdom mfritsch@mmwarburg.com Match in Spritsch United Kingdom mfritsch@mmwarburg.com Match in Spritsch United Kingdom mfritsch@mmwarburg.com Match in Marcel Magiera Sales Trading Oliver Merckel Head of Sales Trading mmwarburg.com Sales Trading mmwarburg.com Sales Trading mmwarburg.com Sales Trading mmwarburg.com Sales Trading bquast Sales Trading bquast Sales Trading bquast@mmwarburg.com Michael Ilgenstein	Scandinavia, Austria	jbuchmueller@mmwarburg.com				
Matthias Fritsch         +49 40 3282-2696 mfritsch@mmwarburg.com         Juliane Niemann Roadshow/Marketing         +49 40 3282-2694 jniemann@mmwarburg.com           SALES TRADING           Oliver Merckel         +49 40 3282-2634 merckel@mmwarburg.com         Marcel Magiera         +49 40 3282-2662           Head of Sales Trading         omerckel@mmwarburg.com         Sales Trading         mmagiera@mmwarburg.com           Elyaz Dust         +49 40 3282-2702         Bastian Quast         +49 40 3282-2701           Sales Trading         edust@mmwarburg.com         Sales Trading         bquast@mmwarburg.com           Michael ligenstein         +49 40 3282-2700 milgenstein@mmwarburg.com         Sales Trading         jtreptow@mmwarburg.com           MACRO RESEARCH         Trading         jtreptow@mmwarburg.com         jtreptow@mmwarburg.com           Macro Research         +49 40 3282-2572 cklude@mmwarburg.com         Dr. Christian Jasperneite lnvestment Strategy         +49 40 3282-2439 cjasperneite@mmwarburg.com           Our research can be found under:         Warburg Research         Research mmwarburg.com/en/index.html         Refinitiv         www.capitaliq.com           FactSet         www.factset.com         Capital IQ         www.capitaliq.com           For access please contact:         Andrea Schaper         +49 40 3282-2632         Kerstin Muthig         +49 40 3282-2						
United Kingdom mfritsch@mmwarburg.com Roadshow/Marketing jniemann@mmwarburg.com  SALES TRADING  Oliver Merckel	,,	9	· ·			
SALES TRADING  Oliver Merckel						
Oliver Merckel +49 40 3282-2634 Marcel Magiera +49 40 3282-2662 Head of Sales Trading omerckel@mmwarburg.com Elyaz Dust +49 40 3282-2702 Bastian Quast +49 40 3282-2701 Sales Trading edust@mmwarburg.com Michael Ilgenstein +49 40 3282-2700 Jörg Treptow +49 40 3282-2658 Sales Trading milgenstein@mmwarburg.com Michael Ilgenstein +49 40 3282-2700 Jörg Treptow +49 40 3282-2658 Sales Trading milgenstein@mmwarburg.com Sales Trading bquast@mmwarburg.com MACRO RESEARCH  Carsten Klude +49 40 3282-2572 Dr. Christian Jasperneite   +49 40 3282-2439   Investment Strategy cjasperneite@mmwarburg.com  Our research can be found under:  Warburg Research research.mmwarburg.com/en/index.html Bloomberg RESP MMWA GO Capital IQ www.refinitiv.com FactSet www.factset.com  For access please contact:  Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703	CALEC TRADING			, 5		
Head of Sales Trading omerckel@mmwarburg.com Elyaz Dust		. 40. 40. 2000. 2001	Manael Maniera	. 10 10 0000 0000		
Elyaz Dust						
Sales Trading edust@mmwarburg.com Michael Ilgenstein	J		5			
Sales Trading milgenstein@mmwarburg.com Sales Trading jtreptow@mmwarburg.com  MACRO RESEARCH  Carsten Klude	-	edust@mmwarburg.com	Sales Trading	bquast@mmwarburg.com		
MACRO RESEARCH  Carsten Klude Macro Research Macro	Michael Ilgenstein		<u> </u>			
Macro Research  Cklude@mmwarburg.com  Investment Strategy  Cjasperneite@mmwarburg.com  Our research can be found under:  Warburg Research  Fesearch.mmwarburg.com/en/index.html  Refinitiv  Capital IQ  Www.capitaliq.com  FactSet  Www.factset.com  For access please contact:  Andrea Schaper  Andrea Schaper  Investment Strategy  Cjasperneite@mmwarburg.com  www.refinitiv.com  Capital IQ  Www.capitaliq.com  FactSet  Kerstin Muthig  +49 40 3282-2703	MACRO RESEARCH	miligenstein@mmwarburg.com	Sales Trauling	Ju-eptow@mmwarburg.com		
Our research can be found under:  Warburg Research research.mmwarburg.com/en/index.html Refinitiv www.refinitiv.com Bloomberg RESP MMWA GO Capital IQ www.capitaliq.com FactSet www.factset.com  For access please contact:  Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703	Carsten Klude					
Warburg Research research.mmwarburg.com/en/index.html Refinitiv www.refinitiv.com Bloomberg RESP MMWA GO Capital IQ www.capitaliq.com FactSet www.factset.com  For access please contact: Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703			cudogj	э,шроннокожниниция,оон		
Bloomberg RESP MMWA GO Capital IQ www.capitaliq.com FactSet www.factset.com  For access please contact: Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703			D 5 W			
FactSet www.factset.com  For access please contact: Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703	-					
For access please contact:  Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703	-		Capital IQ	www.capitaliq.com		
Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703	racioel www.iacisei.com					
·	For access please contact:					
	-					
		. 5		3		